NYSE:JNJ
142.37
0.12
(0.08%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia
Johnson & Johnson
JNJ-N
Analysis and Opinions about JNJ-N
Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
July 10, 2020
(A Top Pick Jul 29/19, Up 10%) He would stick with this one. When a vaccine comes forward, he expects them to bounce up. His model price is $203 -- over 40% upside.
Show full opinionHide full opinion
(A Top Pick Jul 29/19, Up 10%) He would stick with this one. When a vaccine comes forward, he expects them to bounce up. His model price is $203 -- over 40% upside.
COMMENT
COMMENT
June 12, 2020
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
PAST TOP PICK
PAST TOP PICK
June 8, 2020
(A Top Pick May 22/19, Up 9%) He likes the pharma and medical devices areas. He bought when it was suffering from a couple of law suits. They are a minor player in the affected sectors. He likes the healthcare sector.
Show full opinionHide full opinion(A Top Pick May 22/19, Up 9%) He likes the pharma and medical devices areas. He bought when it was suffering from a couple of law suits. They are a minor player in the affected sectors. He likes the healthcare sector.
TOP PICK
TOP PICK
May 11, 2020
It is three different companies: a medical device division; personal care division; and the pharmaceutical division. It continues to execute very well. They are not dependent on their pipeline of drugs. You have a great opportunity to buy a diversified company. There have been some risks on products like talcum powder but they are very good at defending themselves. (Analysts’ price target is $162.10)
Show full opinionHide full opinionIt is three different companies: a medical device division; personal care division; and the pharmaceutical division. It continues to execute very well. They are not dependent on their pipeline of drugs. You have a great opportunity to buy a diversified company. There have been some risks on products like talcum powder but they are very good at defending themselves. (Analysts’ price target is $162.10)
BUY
BUY
May 7, 2020
An excellent company and raised its dividend 55 years in a row. It has done a fantastic job and is a diversified healthcare stock. They have benefited from COVD-19. It is one of the better companies. This gets is whole-hearted support right now.
Show full opinionHide full opinionAn excellent company and raised its dividend 55 years in a row. It has done a fantastic job and is a diversified healthcare stock. They have benefited from COVD-19. It is one of the better companies. This gets is whole-hearted support right now.
TOP PICK
TOP PICK
March 30, 2020
He would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)
Show full opinionHide full opinionHe would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)
TOP PICK
TOP PICK
March 12, 2020
Defensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)
Show full opinionHide full opinionDefensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)
TOP PICK
TOP PICK
February 28, 2020
It's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)
Show full opinionHide full opinionIt's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)
TOP PICK
TOP PICK
February 27, 2020
Model price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)
Show full opinionHide full opinionModel price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)
PAST TOP PICK
PAST TOP PICK
February 26, 2020
(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.
Show full opinionHide full opinion(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.
PAST TOP PICK
PAST TOP PICK
January 21, 2020
(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
Show full opinionHide full opinion(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
BUY
BUY
January 14, 2020
Has long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
Show full opinionHide full opinionHas long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
TOP PICK
TOP PICK
January 10, 2020
His model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
Show full opinionHide full opinionHis model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
TOP PICK
TOP PICK
January 8, 2020
In an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
Show full opinionHide full opinionIn an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
BUY
BUY
December 19, 2019
Given the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
Show full opinionHide full opinionGiven the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
Johnson & Johnson(JNJ-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 12
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 5
Total Signals / Votes : 17
Johnson & Johnson(JNJ-N) Frequently Asked Questions
What is Johnson & Johnson stock symbol?
Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N
Is Johnson & Johnson a buy or a sell?
In the last year, 17 stock analysts published opinions about JNJ-N. 12 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Johnson & Johnson.
Is Johnson & Johnson a good investment or a top pick?
Johnson & Johnson was recommended as a Top Pick by Brian Acker, CA on 2020-07-10. Read the latest stock experts ratings for Johnson & Johnson.
Why is Johnson & Johnson stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Johnson & Johnson worth watching?
17 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.
What is Johnson & Johnson stock price?
On 2020-07-10, Johnson & Johnson (JNJ-N) stock closed at a price of $142.37.
